Kiniksa Pharmaceuticals International plc Class A (KNSA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Kiniksa Pharmaceuticals International plc Class A (KNSA) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (64/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+0.0% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How KNSA Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | 88.5% | 11.4% | $59.0M | $136.4M | 12.4% |
| FY 2024 | $423.2M | 85.6% | -10.8% | -$43.2M | $25.4M | -11.3% |
| FY 2023 | $270.3M | 44% | -9.3% | $14.1M | $1.1M | -0.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring KNSA)
- ✓Live walkthrough of KNSA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
KNSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KNSA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KNSA. Explore sector supply chains on /butterfly.
KNSA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Kiniksa Pharmaceuticals International plc Class A (KNSA)?
In FY 2025 (10-K), KNSA converted $677.6M of revenue into a 88.5% gross margin, 11.4% operating margin, and $136.4M in free cash flow (20.1% FCF margin).